fbpx

Treatment of Antibody Claims In the U.S. After ‘Amgen v. Sanofi’

The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s ruling in ‘Amgen Inc. v. Sanofi,’ a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.

       

Related Articles

Responses

Your email address will not be published. Required fields are marked *